JP2020526503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526503A5 JP2020526503A5 JP2019572539A JP2019572539A JP2020526503A5 JP 2020526503 A5 JP2020526503 A5 JP 2020526503A5 JP 2019572539 A JP2019572539 A JP 2019572539A JP 2019572539 A JP2019572539 A JP 2019572539A JP 2020526503 A5 JP2020526503 A5 JP 2020526503A5
- Authority
- JP
- Japan
- Prior art keywords
- construct
- soluble
- fgf21
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083756A JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529215P | 2017-07-06 | 2017-07-06 | |
| US62/529,215 | 2017-07-06 | ||
| PCT/US2018/040932 WO2019010314A1 (en) | 2017-07-06 | 2018-07-05 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENDOCRINE FGF-RELATED DISEASES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083756A Division JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526503A JP2020526503A (ja) | 2020-08-31 |
| JP2020526503A5 true JP2020526503A5 (https=) | 2021-08-12 |
| JP7316946B2 JP7316946B2 (ja) | 2023-07-28 |
Family
ID=64950347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572539A Active JP7316946B2 (ja) | 2017-07-06 | 2018-07-05 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083756A Pending JP2023103455A (ja) | 2017-07-06 | 2023-05-22 | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11365228B2 (https=) |
| EP (1) | EP3649157A4 (https=) |
| JP (2) | JP7316946B2 (https=) |
| CN (1) | CN110997726B (https=) |
| AU (1) | AU2018297285A1 (https=) |
| CA (1) | CA3069143A1 (https=) |
| WO (1) | WO2019010314A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| HK1214832A1 (zh) | 2012-11-28 | 2016-08-05 | 恩格姆生物制药公司 | 用於代謝病症和疾病治療的組合物和方法 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| MX383664B (es) | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
| WO2021231720A1 (en) * | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113735959B (zh) * | 2021-03-12 | 2023-07-04 | 江南大学 | 一种治疗nash的fgf类似物 |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| WO2025059130A1 (en) * | 2023-09-11 | 2025-03-20 | Yale University | Constructs for modulating fgf21/fgfr/beta-klotho signaling pathway and treating diseases and disorders, and methods thereof |
| CN118852466B (zh) * | 2024-08-08 | 2025-03-28 | 郑州大学第三附属医院(河南省妇幼保健院) | Klotho修饰的CAR-T结构及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| SI2550972T1 (en) | 2007-04-02 | 2018-05-31 | Genentech, Inc. | A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| EP2296690B1 (en) | 2008-06-04 | 2016-11-30 | Amgen, Inc | Fgf21 mutants and uses thereof |
| EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| CA2796055A1 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
| JP5927782B2 (ja) | 2010-06-15 | 2016-06-01 | 国立大学法人広島大学 | 石灰化組織における可溶化Ｋｌｏｔｈｏ、ＦＧＦ２３およびＦＧＦＲ複合体形成機構を利用した用途 |
| MX2013013044A (es) | 2011-05-10 | 2014-02-20 | Amgen Inc | METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO. |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| US9475856B2 (en) * | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
| US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9400677B2 (en) | 2013-01-02 | 2016-07-26 | Apple Inc. | Adaptive handling of priority inversions using transactions |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| AU2015237176A1 (en) | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
| CN107810201A (zh) | 2014-12-04 | 2018-03-16 | 诺华股份有限公司 | 使用klotho变体多肽的方法和组合物 |
| WO2016204884A1 (en) | 2015-06-18 | 2016-12-22 | Albert Einstein College Of Medicine, Inc. | Fgf receptor ligands for treating diabetes and obesity |
| EP3371217B1 (en) * | 2015-11-08 | 2025-06-11 | F. Hoffmann-La Roche AG | Methods of screening for multispecific antibodies |
| WO2017180988A2 (en) * | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| CA3026510A1 (en) | 2016-05-25 | 2017-11-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of secretory disorders |
| WO2018026899A1 (en) | 2016-08-03 | 2018-02-08 | Joslin Diabetes Center, Inc. | Methods and compositions for treating hypoglycemia |
-
2018
- 2018-07-05 AU AU2018297285A patent/AU2018297285A1/en not_active Abandoned
- 2018-07-05 CN CN201880054775.3A patent/CN110997726B/zh active Active
- 2018-07-05 JP JP2019572539A patent/JP7316946B2/ja active Active
- 2018-07-05 CA CA3069143A patent/CA3069143A1/en active Pending
- 2018-07-05 US US16/624,895 patent/US11365228B2/en active Active
- 2018-07-05 EP EP18827563.0A patent/EP3649157A4/en active Pending
- 2018-07-05 WO PCT/US2018/040932 patent/WO2019010314A1/en not_active Ceased
-
2023
- 2023-02-28 US US18/176,172 patent/US12534503B2/en active Active
- 2023-05-22 JP JP2023083756A patent/JP2023103455A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526503A5 (https=) | ||
| JP2020500885A5 (https=) | ||
| JP7215997B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 | |
| Kuo et al. | Neonatal Fc receptor: from immunity to therapeutics | |
| JP5199876B2 (ja) | 一価ＩｇＧを生成するための方法 | |
| JP7575862B2 (ja) | デュアル機能タンパク質およびそれを含む医薬組成物 | |
| US9708412B2 (en) | Trispecific binding proteins and methods of use | |
| JP5564268B2 (ja) | 成長因子と結合する融合タンパク質 | |
| ES2677111T3 (es) | Mejora del transporte de moléculas terapéuticas a través de la barrera hematoencefálica | |
| JP2023103455A5 (https=) | ||
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2025114622A (ja) | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| CN116987189A (zh) | 单链可变片段cd3结合蛋白质 | |
| CN102666586A (zh) | 具有延长的半衰期的药物融合体和缀合物 | |
| TW202035440A (zh) | 新穎合理設計的蛋白質組合物 | |
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| JP2016532448A (ja) | Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質 | |
| JP2008500373A5 (https=) | ||
| JP2021535727A5 (https=) | ||
| JP7649923B2 (ja) | ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用 | |
| US20120058116A1 (en) | Fgfr1c antibody combinations | |
| JP2025509401A (ja) | 頭頸部がん治療のための三重複合薬物投与療法 | |
| TWI723247B (zh) | 重組蛋白及其用途 | |
| JPWO2021247604A5 (https=) |